Another Multiple Sclerosis Winner for Biogen


In this video, health-care analyst David Williamson discusses Biogen's latest drug up for FDA approval. The big biotech is on a roll lately: The FDA recently accepted applications for two hemophelia drugs and today came news of multiple sclerosis drug Plegridy. This is a longer-lasting, and therefore less-injected, version of the company's flagship product Avonex.

Watch and find out why this submission is important for expanding Avonex's sales and why it may help protect the franchise from its biggest threat, another recently approved Biogen MS drug.

Another topic health-care investors need to keep up on is Obamacare, as the law will undoubtedly have far-reaching effects. The Motley Fool's new free report, "Everything You Need to Know About Obamacare," lets you know how your health insurance, your taxes, and your portfolio will be affected. Click here to read more.

The article Another Multiple Sclerosis Winner for Biogen originally appeared on

David Williamson and The Motley Fool have no position in any stocks mentioned. Follow David on Twitter @MotleyDavid. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.